# US 2026/0083844 A1 · Downregulating inos to increase car-t killing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083844 A1
- Document ID: US20260083844A1
- Status: Published application
- Kind: A1
- Application number: 19/109,722
- Filed: 2023-09-15
- Published: 2026-03-26
- Earliest claimed: 2022-09-15
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute Inc.
- Inventors: Marco DAVILA; Sae Bom LEE
- Web page: https://patentgrep.com/patent/US20260083844A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/381: having five-membered rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4164: 1,3-Diazoles
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 16/249: {Interferons}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 2239/10: characterized by the structure of the chimeric antigen receptor [CAR]
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.

## Claims

### Claim 1

A method for enhancing anti-tumor efficacy of immune effector cells in a subject, comprising administering to the subject an effective amount of a composition comprising a nitric oxide synthase (NOS) inhibitor, interferon gamma (IFN-γ) inhibitor, or combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NOS inhibitor is a NOS2-specific inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the NOS inhibitor is a non-selective NOS inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the NOS inhibitor comprises at least one member selected from the group consisting of N-[4-(2-{[(3-chlorophenyl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximide dihydrochloride, 7-nitroindazole, 1-(2-trifluoromethylphenyl) imidazole, [N5-(1-imino-3-butenyl)-L-ornithine], 3-bromo-7-nitroindazole, and S-ethyl-N-[4-(trifluoromethyl)phenyl) isothiourea HCl.

### Claim 5 (depends on 1)

The method of claim 1, wherein the IFN-γ inhibitor is an IFN-γ neutralizing antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the IFN-γ inhibitor is a gene silencing oligonucleotide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune effector cell is selected from the group consisting of an alpha-beta T cells, a gamma-delta T cell, a Natural Killer (NK) cells, a Natural Killer T (NKT) cell, a B cell, an innate lymphoid cell (ILC), a cytokine induced killer (CIK) cell, a cytotoxic T lymphocyte (CTL), a lymphokine activated killer (LAK) cell, and a regulatory T cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the immune effector cell is a CAR-T cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein the immune effector cell is a tumor infiltrating lymphocyte (TIL).

### Claim 10 (depends on 1)

The method of claim 1, wherein the immune effector cell is engineered to express the NOS inhibitor or IFN-γ inhibitor.
